The Antibody Characterization Laboratory is a reference program that develops antibodies for the scientific community, including extensive antibody characterization data and protocols. 

The laboratory uses an array of techniques to determine the properties of antibodies and other renewable reagents that can be used in cancer-related research. All the reagents, associated data, and standard operating procedures are readily available as part of the National Cancer Institute’s Antibody Portal

Antibody validation: A community resource 

The data we generate is designed to help researchers select the optimal antibodies for their experiments. They have access to our methods to perform quality-control studies or biological assays. 

944 antibodies developed to 568 antigen targets to date.
Antibody Characterization Laboratory

 

 

Graphic representation of antibodies
Researcher Resource

Access the Antibody Portal

The Antibody Characterization Laboratory performs antibody validation as part of a community resource overseen by the National Cancer Institute Office of Cancer Clinical Proteomics Research. You may access the data standards and reference materials online and filter by your criteria. You can browse by antibody or reagent.

Access NCI-60 cell lines 

Our scientists subject each antibody to informative assays and techniques that collectively reveal a comprehensive picture of its characteristics. We provide our approaches, standardized methods, and the complete characterization data (both positive and negative results). Our ready access to the NCI-60 human cancer cell lines makes our program a distinct, if not unique, resource.  

Additional Content

Immunization process for call-out antibodies 

Initial screenings identify potential candidates, further validated in the technique of interest (immunohistochemistry, immunoprecipitation flow cytometry, and other assays). The selected purified antibody is tested, with particular attention to endogenous detection, using Western blotting applications (cell or tissue lysates) and cell-based applications. We collaborate with investigators from both internal (National Institutes of Health) and external institutions (academia).   

Our capabilities and specializations

Additional Content

Characterization process and pipeline 

Our scientists produce up to three affinity reagents for each expressed and purified antigen, and one affinity reagent per peptide. We characterize selected reagents using specialized processes. 

Additional Content
  • Western blot (including automated Western and single-cell Western) 

  • Surface plasmon resonance  

  • Bio-Layer Interferometry  

  • ELISA 

  • Mass spectrometry immunoassay  

  • Immunohistochemistry  

  • NCI-60 Protein Array 

  • Immunofluorescence 

  • Flow Cytometry 

  • Immunoprecipitation 

Immunofluorescence staining using CPTC-ITGA11-1 as primary antibody against human mesenchymal stem cells
Monoclonal antibody targeting Integrin alpha 11

Need for renewable reagent for the detection of ITGA11 for model glioma studies

We developed and characterized CPTC-ITGA11-1, a rabbit monoclonal antibody that can detect the target in IHC with high affinity. The antibody is now available for our collaborator’s research, and to the broader scientific community.
Antibody graphic
Quantify Immunomodulatory proteins

Supporting correlative studies in immunotherapy clinical trials

Assays and novel monoclonal antibodies are publicly available to the biomedical community.